The role of the carboxyl-terminal sequence of tau and MAP2 in the pathogenesis of Dementia

Frontiers in Molecular Neuroscience

Volumn 9, Issue DEC2016, 2016, Pages

  Xie, Ce ^a,b   Miyasaka, Tomohiro ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DOSHISHA UNIVERSITY   (Japan)

Author keywords

Alzheimer s disease; Inclusion; MAP2; Microtubule associated protein 2; Tau; Tauopathy

Indexed keywords

MICROTUBULE ASSOCIATED PROTEIN 2; TAU PROTEIN;

CAENORHABDITIS ELEGANS; CARBOXY TERMINAL SEQUENCE; DEMENTIA; HUMAN; NONHUMAN; REVIEW;

EID: 85010961057     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2016.00158     Document Type: Review

References (53)

1. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., and Hyman, B. T. (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42, 631–639.
2. Braak, H., and Braak, E. (1997). Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351–357.
3. Braak, E., Braak, H., and Mandelkow, E. M. (1994). A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 87, 554–567.
4. Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., et al. (2011). The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2:252.
5. Coppola, G., Chinnathambi, S., Lee, J. J., Dombroski, B. A., Baker, M. C., Soto-Ortolaza, A. I., et al. (2012). Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer’s diseases. Hum. Mol. Genet. 21, 3500–3512.
6. Cowan, C. M., and Mudher, A. (2013). Are tau aggregates toxic or protective in tauopathies? Front. Neurol. 4:114.
7. Decker, J. M., Krüger, L., Sydow, A., Zhao, S., Frotscher, M., Mandelkow, E., et al. (2015). Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca++ dysregulation. Acta Neuropathol. Commun. 3:23.
8. Dehmelt, L., and Halpain, S. (2005). The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 6:204.
9. Delacourte, A., David, J. P., Sergeant, N., Buée, L., Wattez, A., Vermersch, P., et al. (1999). The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology 52, 1158–1165.
10. Giacobini, E., and Gold, G. (2013). Alzheimer disease therapy—moving from amyloid-β to tau. Nat. Rev. Neurol. 9, 677–686.
11. Gilley, J., Ando, K., Seereeram, A., Rodríguez-Martín, T., Pooler, A. M., Sturdee, L., et al. (2016). Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tauknockin mice. Neurobiol. Aging 39, 1–18.
12. Goedert, M., Crowther, R. A., and Spillantini, M. G. (1998). Tau mutations cause frontotemporal dementias. Neuron 21, 955–958.
13. Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., and Crowther, R. A. (1996). Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550–553.
14. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., et al. (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann. Neurol. 41, 17–24.
15. Gorsky, M. K., Burnouf, S., Dols, J., Mandelkow, E., and Partridge, L. (2016). Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo. Sci. Rep. 6:22685.
16. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353–356.
17. Hochgräfe, K., Sydow, A., Matenia, D., Cadinu, D., Könen, S., Petrova, O., et al. (2015). Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol. Commun. 3:25.
18. Jakes, R., Novak, M., Davison, M., and Wischik, C. M. (1991). Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer’s disease. EMBO J. 10, 2725–2729.
19. Kadavath, H., Hofele, R. V., Biernat, J., Kumar, S., Tepper, K., Urlaub, H., et al. (2015). Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc. Natl. Acad. Sci. U S A 112, 7501–7506.
20. Khlistunova, I., Biernat, J., Wang, Y., Pickhardt, M., von Bergen, M., Gazova, Z., et al. (2006). Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281, 1205–1214.
21. Kimura, T., Whitcomb, D. J., Jo, J., Regan, P., Piers, T., Heo, S., et al. (2013). Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369:20130144.
22. Kondo, J., Honda, T., Mori, H., Hamada, Y., Miura, R., Ogawara, M., et al. (1988). The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1, 827–834.
23. Kosik, K. S., Duffy, L. K., Dowling, M. M., Abraham, C., McCluskey, A., and Selkoe, D. J. (1984). Microtubule-associated protein 2: monoclonal antibodies demonstrate the selective incorporation of certain epitopes into Alzheimer neurofibrillary tangles. Proc. Natl. Acad. Sci. U S A 81, 7941–7945.
24. Kuchibhotla, K. V., Wegmann, S., Kopeikina, K. J., Hawkes, J., Rudinskiy, N., Andermann, M. L., et al. (2014). Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc. Natl. Acad. Sci. U S A 111, 510–514.
25. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muoz, M. J., Jackson, G. R., and Kayed, R. (2010). Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039–10041.
26. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., and Kayed, R. (2011). Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol. Neurodegener. 6:39.
27. Li, J., and Le, W. (2013). Modeling neurodegenerative diseases in Caenorhabditis elegans. Exp. Neurol. 250, 94–103.
28. Maeda, S., Djukic, B., Taneja, P., Yu, G. Q., Lo, I., Davis, A., et al. (2016). Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep. 17, 530–551.
29. Mandelkow, E. M., and Mandelkow, E. (2012). Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2:a006247.
30. Markaki, M., and Tavernarakis, N. (2010). Modeling human diseases in Caenorhabditis elegans. Biotechnol. J. 5, 1261–1276.
31. Miyasaka, T., Watanabe, A., Saito, Y., Murayama, S., Mann, D. M., Yamazaki, M., et al. (2005). Visualization of newly deposited tau in neurofibrillary tangles and neuropil threads. J. Neuropathol. Exp. Neurol. 64, 665–674.
32. Miyasaka, T., Xie, C., Yoshimura, S., Shinzaki, Y., Yoshina, S., Kage-Nakadai, E., et al. (2016). Curcumin improves tau-induced neuronal dysfunction of nematodes. Neurobiol. Aging 39, 69–81.
33. Mocanu, M. M., Nissen, A., Eckermann, K., Khlistunova, I., Biernat, J., Drexler, D., et al. (2008). The potential for β-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss and coassembly with endogenous Tau in inducible mouse models of tauopathy. J. Neurosci. 28, 737–748.
34. Momeni, P., Pittman, A., Lashley, T., Vandrovcova, J., Malzer, E., Luk, C., et al. (2009). Clinical and pathological features of an Alzheimer’s disease patient with the MAPT ∆K280 mutation. Neurobiol. Aging 30, 388–393.
35. Nukina, N., Kosik, K. S., and Selkoe, D. J. (1987). Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. Proc. Natl. Acad. Sci. U S A 84, 3415–3419.
36. Patterson, K. R., Remmers, C., Fu, Y., Brooker, S., Kanaan, N. M., Vana, L., et al. (2011). Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 286, 23063–23076.
37. Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., and Ferreira, A. (2002). Tau is essential to β-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U S A 99, 6364–6369.
38. Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., et al. (2007). Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer’s disease mouse model. Science 316, 750–754.
39. Rosemblatt, M., Fellous, A., Mazie, J. C., Delacourte, A., and Defossez, A. (1989). Alzheimer’s disease: microtubule-associated proteins 2 (MAP2) are not components of paired helical filaments. FEBS Lett. 252, 91–94.
40. Sanders, D. W., Kaufman, S. K., DeVos, S. L., Sharma, A. M., Mirbaha, H., Li, A., et al. (2014). Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271–1288.
41. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481.
42. Spillantini, M. G., and Goedert, M. (2000). Tau mutations in familial frontotemporal dementia. Brain 123, 857–859.
43. Spillantini, M. G., and Goedert, M. (2013). Tau pathology and neurodegeneration. Lancet Neurol. 12, 609–622.
44. Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., et al. (1999). Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. 155, 2153–2165.
45. Taniguchi-Watanabe, S., Arai, T., Kametani, F., Nonaka, T., Masuda-Suzukake, M., Tarutani, A., et al. (2016). Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometricanalyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 131, 267–280.
46. von Bergen, M., Friedhoff, P., Biernat, J., Heberle, J., Mandelkow, E. M., and Mandelkow, E. (2000). Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming β structure. Proc. Natl. Acad. Sci. U S A 97, 5129–5134.
47. West, S., and Bhugra, P. (2015). Emerging drug targets for Aβ and tau in Alzheimer’s disease: a systematic review. Br. J. Clin. Pharmacol. 80, 221–234.
48. Wheeler, J. M., McMillan, P. J., Hawk, M., Iba, M., Robinson, L., Xu, G. J., et al. (2015). High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration. Acta Neuropathol. Commun. 3:33.
49. Wischik, C. M., Novak, M., Thøgersen, H. C., Edwards, P. C., Runswick, M. J., Jakes, R., et al. (1988). Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. U S A 85, 4506–4510.
50. Xie, C., Miyasaka, T., Yoshimura, S., Hatsuta, H., Yoshina, S., Kage-Nakadai, E., et al. (2014). The homologous carboxyl-terminal domains of microtubule-associated protein 2 and Tau induce neuronal dysfunction and have differential fates in the evolution of neurofibrillary tangles. PLoS One 9:e89796.
51. Xie, C., Soeda, Y., Shinzaki, Y., In, Y., Tomoo, K., Ihara, Y., et al. (2015). Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau. J. Neurochem. 135, 19–26.
52. Xu, L., Zheng, J., Margittai, M., Nussinov, R., and Ma, B. (2016). How does Hyperphosphorylation promote tau aggregation and filament structure and stability? ACS Chem Neurosci. 7, 565–575.
53. Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., et al. (2012). Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol. 8, 393–399.